The Feasibility of Using CT-Guided ROI for Semiquantifying Striatal Dopamine Transporter Availability in a Hybrid SPECT/CT System

A hybrid SPECT/CT system provides accurate coregistration of functional and morphological images. CT-guided region of interest (ROI) for semiquantifying striatal dopamine transporter (DAT) availability may be a feasible method. We therefore assessed the intra- and interobserver reproducibility of manual SPECT and CT-guided ROI methods and compared their semiquantitative data with data from MRI-guided ROIs. We enrolled twenty-eight patients who underwent Tc-99m TRODAT-1 brain SPECT/CT and brain MRI. ROIs of the striatal, caudate, putamen, and occipital cortex were manually delineated on the SPECT, CT, and MRI. ROIs from CT and MRI were transferred to the coregistered SPECT for semiquantification. The striatal, caudate, and putamen nondisplaceable binding potential (BPND) were calculated. Using CT-guided ROIs had higher intra- and interobserver concordance correlation coefficients, closer Bland-Altman biases to zero, and narrower limits of agreement than using manual SPECT ROIs. The correlation coefficients of striatal, caudate, and putamen BPND were good between manual SPECT and MRI-guided ROI methods and even better between CT-guided and MRI-guided ROI methods. Conclusively, CT-guided ROI delineation for semiquantifying striatal DAT availability in a hybrid SPECT/CT system is highly reproducible, and the semiquantitative data correlate well with data from MRI-guided ROIs.

[1]  J. Cummings,et al.  The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. , 2011, Brain : a journal of neurology.

[2]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[3]  Brad J Kemp,et al.  Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. , 2006, Seminars in nuclear medicine.

[4]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  N. Peng,et al.  An incidental finding of cerebral meningioma on 99mTc-TRODAT-1 dopamine transporter SPECT/CT. , 2012, Clinical nuclear medicine.

[6]  C. Halldin,et al.  Molecular Imaging of the Dopamine Transporter , 2010, The Journal of Nuclear Medicine.

[7]  A. Alavi,et al.  Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Rakesh Kumar,et al.  SPECT-CT in routine clinical practice: increase in patient radiation dose compared with SPECT alone , 2012, Nuclear medicine communications.

[9]  Robert B. McBride,et al.  A proposal for strength-of-agreement criteria for Lins Concordance Correlation Coefficient , 2005 .

[10]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[11]  Christoph Scherfler,et al.  Dopamine transporter SPECT: How to remove subjectivity? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[12]  D. Jennings,et al.  Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients , 2007, Journal of Nuclear Medicine.

[13]  Wen-Sheng Huang,et al.  Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson’s disease , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Yi-Hsin Weng,et al.  Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  A. Paschali,et al.  Dopamine Transporter SPECT/CT and Perfusion Brain SPECT Imaging in Idiopathic Basal Ganglia Calcinosis , 2009, Clinical nuclear medicine.

[16]  P. Piccini.  Dopamine transporter: Basic aspects and neuroimaging , 2003, Movement disorders : official journal of the Movement Disorder Society.

[17]  G. Mahon.  A Proposal for Strength-of-Agreement Criteria for Lin’s Concordance Correlation Coefficient , 2005 .

[18]  C. Svarer,et al.  Validation of a Method for Accurate and Highly Reproducible Quantification of Brain Dopamine Transporter SPECT Studies , 2011, The Journal of Nuclear Medicine Technology.

[19]  T. Yen,et al.  Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT. , 2007, Nuclear medicine and biology.

[20]  John Seibyl,et al.  SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.

[21]  Rosemary J Morton,et al.  Comparison of different methods of DatSCAN quantification , 2005, Nuclear medicine communications.

[22]  Klemens Scheidhauer,et al.  SPECT-CT , 2008, Journal of Nuclear Medicine.

[23]  Laurent Degos,et al.  HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS , 1974 .

[24]  Nikolaos Karatzas,et al.  SPECT imaging evaluation in movement disorders: far beyond visual assessment , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  William H. Judy,et al.  The Measurement, Reporting, and Management of Radiation Dose in CT , 2008 .

[26]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Z. Meng,et al.  Evaluation of Tourette’s syndrome by 99mTc-TRODAT-1 SPECT/CT imaging , 2010, Annals of nuclear medicine.

[28]  P. Dupont,et al.  The Role of CT-Based Attenuation Correction and Collimator Blurring Correction in Striatal Spect Quantification , 2011, International journal of molecular imaging.

[29]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[30]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  Torsten Kuwert,et al.  A review on the clinical uses of SPECT/CT , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Rene Donner,et al.  Fully automated 3D basal ganglia activity measurement in dopamine transporter scintigraphy (Spectalyzer) , 2010, Annals of nuclear medicine.